Jump to content
Sign in to follow this  

Cymbalta (Duloxetine) Information

Recommended Posts

CYMBALTA® is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for:
•    Major Depressive Disorder (MDD)
•    Generalized Anxiety Disorder (GAD)
•    Diabetic Peripheral Neuropathic Pain (DPNP)
•    Fibromyalgia (FM)
•    Chronic Musculoskeletal Pain

Dosage, Dosage Types
- Take CYMBALTA once daily, with or without food.

- Swallow CYMBALTA whole; do not crush or chew, do not open capsule. Take a missed dose as soon as it is remembered.

- Do not take two doses of CYMBALTA at the same time. 

- 20 mg, 30 mg, and 60 mg delayed-release capsules

•    Pregnancy: may cause fetal harm
•    Nursing Mothers: Exercise caution, only use under doctor's care
•    Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with CYMBALTA or within 5 days of stopping treatment with CYMBALTA. Do not use CYMBALTA within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start CYMBALTA in a patient who is being treated with linezolid or intravenous methylene blue
•    Hepatotoxicity: Hepatic failure, sometimes fatal, has been reported in patients treated with CYMBALTA. CYMBALTA should be discontinued in patients who develop jaundice or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established. CYMBALTA should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease
•    Orthostatic Hypotension, Falls and Syncope: Cases have been reported with CYMBALTA therapy
•    Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including with CYMBALTA, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort). If such symptoms occur, see your doctor as soon as possible. 
•    Abnormal Bleeding: CYMBALTA may increase the risk of bleeding events. There is a risk of bleeding associated with the concomitant use of CYMBALTA and NSAIDs, aspirin, or other drugs that affect coagulation 
•    Severe Skin Reactions: Severe skin reactions, including erythema multiforme and Stevens-Johnson Syndrome (SJS), can occur with CYMBALTA. CYMBALTA should be discontinued at the first appearance of blisters, peeling rash, mucosal erosions, or any other sign of hypersensitivity if no other etiology can be identified.
•    Discontinuation: May result in symptoms, including dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue
•    Activation of mania or hypomania has occurred
•    Angle-Closure Glaucoma: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants.
•  Blood pressure should be monitored
•  Doctor shoukd be aware if uou have seizure didorder.
•    Hyponatremia: Cases of hyponatremia have been reported
•    Glucose Control in Diabetes: In diabetic peripheral neuropathic pain patients, small increases in fasting blood glucose, and HbA1c have been observed
•    Conditions that Slow Gastric Emptying: Use cautiously.
•    Urinary Hesitation and Retention
Adverse Reactions
•    Most common adverse reactions:  nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis.
To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Revised: 12/2017
Eli Lilly and Company

The Information supplied here on Depression Forums  is not a substitute for medical advice from a health professional or your own doctor.

Share this post

Link to post
Share on other sites
This topic is now closed to further replies.
Sign in to follow this  

  • Create New...